Clinical and economic burden of invasive fungal diseases in Europe: focus on pre-emptive and empirical treatment of Aspergillus and Candida species

Drgona, L., Khachatryan, A., Stephens, J., Charbonneau, C., Kantecki, M., Haider, S. and Barnes, Rosemary Ann 2014. Clinical and economic burden of invasive fungal diseases in Europe: focus on pre-emptive and empirical treatment of Aspergillus and Candida species. European Journal of Clinical Microbiology & Infectious Diseases 33 (1) , pp. 7-21. 10.1007/s10096-013-1944-3

Preview

PDF - Published Version Available under License Creative Commons Attribution. Download (487kB) | Preview

Abstract

Invasive fungal diseases (IFDs) have been widely studied in recent years, largely because of the increasing population at risk. Aspergillus and Candida species remain the most common causes of IFDs, but other fungi are emerging. The early and accurate diagnosis of IFD is critical to outcome and the optimisation of treatment. Rapid diagnostic methods and new antifungal therapies have advanced disease management in recent years. Strategies for the prevention and treatment of IFDs include prophylaxis, and empirical and pre-emptive therapy. Here, we review the available primary literature on the clinical and economic burden of IFDs in Europe from 2000 to early 2011, with a focus on the value and outcomes of different approaches.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine
Subjects:	Q Science > QR Microbiology R Medicine > RM Therapeutics. Pharmacology
Publisher:	Springer
ISSN:	0934-9723
Date of First Compliant Deposit:	30 March 2016
Last Modified:	09 May 2023 11:19
URI:	https://orca.cardiff.ac.uk/id/eprint/61475

Citation Data

Cited 82 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item